The amyotrophic lateral sclerosis treatment market valued for $662.25 million in 2022 and is estimated to reach $1.03 Billion by 2032, exhibiting a CAGR of 4.6% from 2023 to 2032.
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS causes these nerve cells to gradually break down and die, which results in the loss of muscle control and eventual paralysis. The symptoms of ALS typically begin with muscle weakness or stiffness, often in the hands or feet, and gradually spread to other parts of the body. Other symptoms include difficulty speaking, swallowing, or breathing, as well as muscle cramps and twitching. There is currently no cure for ALS, and treatment mainly focuses on managing symptoms and improving the quality of life for people with the disease.
Some of the drugs that are commonly used to treat amyotrophic lateral sclerosis include Riluzole, Edaravone, and Sodium phenylbutyrate and taurursodio. Riluzole works by reducing the release of glutamate, a neurotransmitter that damage motor neurons and Edaravone is a free radical scavenger that works by reducing oxidative stress in the body, which damage the motor neurons.
The major factors that drive the growth of the global amyotrophic lateral sclerosis treatment market include, increase in prevalence of amyotrophic lateral sclerosis, and rise in approval of new drugs and therapies for ALS. The incidence of ALS is expected to rise, as the global population ages, leading to a growth in demand for treatments and therapies that may help to manage the symptoms and slow the progression of the disease.
Another market driver is the growth in awareness and understanding of ALS among healthcare professionals, patients, and caregivers. There is a greater understanding of the underlying mechanisms of ALS and potential targets for treatment with more research being done on the disease and advances in medical technology. This has led to the development of new therapies, such as gene therapies and stem cell treatments, which are expected to drive market growth during the forecast period.
In addition, regulatory frameworks and reimbursement policies may also impact the market for ALS treatments. The approval of new drugs and therapies by regulatory bodies, such as the U.S. FDA, may drive market growth by providing patients with access to new and innovative treatments. For instance, increase in pipeline products such as Tofersen, ANX005 and others for treating an amyotrophic lateral sclerosis which is anticipated to provide lucrative opportunities to the market players. Reimbursement policies that provide coverage for these treatments can also help to expand the market by making them more accessible and affordable for patients.
However, limited understanding of the disease, stringent regulatory process for approving new treatments for ALS, which can delay the availability of new therapies for patients and higher treatment may restrict the market growth.
The amyotrophic lateral sclerosis treatment market is segmented into drug, type, distribution channel, and region. On the basis of drug, the market is categorized into Riluzole, Edaravone, and others. On the basis of type, the market is bifurcated into sporadic ALS and familial ALS. On the basis of distribution channel, the market is classified into hospital pharmacies, online providers, and drug stores & retail pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Major key players that operate in the global amyotrophic lateral sclerosis treatment market are Aquestive Therapeutics, Inc., Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Viatris Inc., Amylyx Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Otsuka Pharmaceutical Co., Ltd., Covis Pharma GmbH, ITALFARMACO S.p.A., and Alkem Laboratories Ltd. Key players operating in the market have adopted product approval, agreement, and product launch as their key strategies to expand their product portfolio. For instance, in January 2023, Amylyx Pharmaceuticals, Inc. announced it has entered into an exclusive license and distribution agreement with Neopharm in which Neopharm is expected to commercialize to regulatory review and approval of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS) in Israel, Gaza, West Bank, and the Palestinian.
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS causes these nerve cells to gradually break down and die, which results in the loss of muscle control and eventual paralysis. The symptoms of ALS typically begin with muscle weakness or stiffness, often in the hands or feet, and gradually spread to other parts of the body. Other symptoms include difficulty speaking, swallowing, or breathing, as well as muscle cramps and twitching. There is currently no cure for ALS, and treatment mainly focuses on managing symptoms and improving the quality of life for people with the disease.
Some of the drugs that are commonly used to treat amyotrophic lateral sclerosis include Riluzole, Edaravone, and Sodium phenylbutyrate and taurursodio. Riluzole works by reducing the release of glutamate, a neurotransmitter that damage motor neurons and Edaravone is a free radical scavenger that works by reducing oxidative stress in the body, which damage the motor neurons.
The major factors that drive the growth of the global amyotrophic lateral sclerosis treatment market include, increase in prevalence of amyotrophic lateral sclerosis, and rise in approval of new drugs and therapies for ALS. The incidence of ALS is expected to rise, as the global population ages, leading to a growth in demand for treatments and therapies that may help to manage the symptoms and slow the progression of the disease.
Another market driver is the growth in awareness and understanding of ALS among healthcare professionals, patients, and caregivers. There is a greater understanding of the underlying mechanisms of ALS and potential targets for treatment with more research being done on the disease and advances in medical technology. This has led to the development of new therapies, such as gene therapies and stem cell treatments, which are expected to drive market growth during the forecast period.
In addition, regulatory frameworks and reimbursement policies may also impact the market for ALS treatments. The approval of new drugs and therapies by regulatory bodies, such as the U.S. FDA, may drive market growth by providing patients with access to new and innovative treatments. For instance, increase in pipeline products such as Tofersen, ANX005 and others for treating an amyotrophic lateral sclerosis which is anticipated to provide lucrative opportunities to the market players. Reimbursement policies that provide coverage for these treatments can also help to expand the market by making them more accessible and affordable for patients.
However, limited understanding of the disease, stringent regulatory process for approving new treatments for ALS, which can delay the availability of new therapies for patients and higher treatment may restrict the market growth.
The amyotrophic lateral sclerosis treatment market is segmented into drug, type, distribution channel, and region. On the basis of drug, the market is categorized into Riluzole, Edaravone, and others. On the basis of type, the market is bifurcated into sporadic ALS and familial ALS. On the basis of distribution channel, the market is classified into hospital pharmacies, online providers, and drug stores & retail pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Major key players that operate in the global amyotrophic lateral sclerosis treatment market are Aquestive Therapeutics, Inc., Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Viatris Inc., Amylyx Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Otsuka Pharmaceutical Co., Ltd., Covis Pharma GmbH, ITALFARMACO S.p.A., and Alkem Laboratories Ltd. Key players operating in the market have adopted product approval, agreement, and product launch as their key strategies to expand their product portfolio. For instance, in January 2023, Amylyx Pharmaceuticals, Inc. announced it has entered into an exclusive license and distribution agreement with Neopharm in which Neopharm is expected to commercialize to regulatory review and approval of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS) in Israel, Gaza, West Bank, and the Palestinian.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the amyotrophic lateral sclerosis treatment market analysis from 2022 to 2032 to identify the prevailing amyotrophic lateral sclerosis treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the amyotrophic lateral sclerosis treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global amyotrophic lateral sclerosis treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drugs
- Riluzole
- Edaravone
- Others
By Type
- Sporadic ALS
- Familial ALS
By Distribution Channel
- Hospital Pharmacies
- Online Providers
- Drug Stores and Retail Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Alkem Laboratories Ltd
- Amylyx Pharmaceuticals, Inc.
- Aquestive Therapeutics, Inc.
- Covis Pharma GmbH
- Glenmark Pharmaceuticals Limited
- ITALFARMACO S.p.A.
- Mitsubishi Chemical Group Corporation
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS
CHAPTER 5: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE
CHAPTER 6: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Alkem Laboratories Ltd
- Amylyx Pharmaceuticals, Inc.
- Aquestive Therapeutics, Inc.
- Covis Pharma GmbH
- Glenmark Pharmaceuticals Limited
- ITALFARMACO S.p.A.
- Mitsubishi Chemical Group Corporation
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
